Enliven Therapeutics reported net income of -$37.21M for the quarter ended Jun 2026. This income statement covers 30 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 6.57M | 5.42M | 6.57M | 6.57M | 6.57M | 6.57M | 18.51M | 41.15M | 41.20M | 41.29M | 46.78M | 47.17M | 47.25M | 48.94M | 49.04M | 59.23M | 59.26M | 59.44M | 60.89M | 73.25M | ||||||||||
| Operating items | ||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 10.40M | 10.86M | 7.06M | 7.94M | 7.83M | 8.20M | 11.88M | 15.18M | 19.61M | 17.91M | 19.97M | 18.83M | 21.26M | 20.72M | 24.89M | 21.49M | 18.23M | 21.25M | 20.69M | 29.00M | ||||||||||
| Selling, General & AdministrativeSG&A | 3.26M | 3.48M | 1.62M | 1.08M | 3.10M | 1.97M | 4.54M | 4.95M | 4.64M | 4.82M | 6.02M | 5.78M | 5.81M | 6.17M | 6.80M | 7.09M | 6.87M | 13.04M | 7.14M | 8.21M | ||||||||||
| Operating ExpensesOpex | 13.66M | 14.33M | 8.68M | 9.02M | 10.93M | 10.16M | 16.42M | 20.13M | 24.25M | 22.73M | 25.99M | 24.60M | 27.07M | 26.90M | 31.69M | 28.58M | 25.10M | 34.28M | 27.82M | 37.21M | ||||||||||
| Operating IncomeOp. Inc | -13.66M | -14.33M | -8.68M | -9.02M | -10.93M | -10.16M | -16.42M | -20.13M | -24.25M | -22.73M | -25.99M | -24.60M | -27.07M | -26.90M | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M | ||||||||||
| EBIT | -13.66M | -14.33M | -8.68M | -9.02M | -10.93M | -10.16M | -16.42M | -20.13M | -24.25M | -22.73M | -25.99M | -24.60M | -27.07M | -26.90M | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M | ||||||||||
| Non-operating items | ||||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.02M | -0.06M | -0.06M | -0.04M | -0.01M | -0.01M | -0.00M | -0.00M | -0.05M | -0.00M | -0.01M | |||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.01M | 0.01M | 0.01M | 0.13M | 0.38M | 0.61M | 1.69M | 3.41M | 3.48M | 3.36M | 3.25M | 4.65M | 3.91M | 3.72M | 3.15M | 3.25M | 4.95M | 4.62M | 4.20M | 4.72M | ||||||||||
| Net income details | ||||||||||||||||||||||||||||||
| EBT | -13.66M | -14.33M | -8.68M | -9.02M | -10.93M | -10.16M | -16.42M | -20.13M | -24.25M | -22.73M | -25.99M | -24.60M | -27.07M | -26.90M | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M | ||||||||||
| Tax ProvisionsTaxes | 0.23M | |||||||||||||||||||||||||||||
| Profit After TaxPAT | -13.66M | -14.33M | -8.68M | -9.02M | -10.93M | -10.16M | -16.42M | -20.13M | -24.25M | -22.73M | -25.99M | -24.84M | -27.07M | -26.90M | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M | ||||||||||
| Income from Continuing OperationsIncome (Continuing) | -13.66M | -14.33M | -8.68M | -9.02M | -10.93M | -10.16M | -16.42M | -20.13M | -24.25M | -22.73M | -25.99M | -24.84M | -27.07M | -26.90M | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M | ||||||||||
| Consolidated Net IncomeConsol Net Inc. | -13.66M | -14.33M | -8.68M | -9.02M | -10.93M | -10.16M | -16.42M | -20.13M | -24.25M | -22.73M | -25.99M | -24.84M | -27.07M | -26.90M | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M | ||||||||||
| Income towards Parent CompanyParent Net Inc | -13.65M | -14.32M | -8.67M | -8.89M | -10.55M | -9.55M | -14.72M | -16.72M | -20.77M | -19.37M | -22.74M | -19.95M | -23.16M | -23.18M | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M | -32.48M | ||||||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -13.65M | -14.32M | -14.64M | -11.45M | -4.61M | 32.19M | -14.72M | -16.72M | -20.77M | -19.37M | -22.74M | -19.95M | -23.16M | -23.18M | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M | -32.48M | ||||||||||
| Additional items | ||||||||||||||||||||||||||||||
| EPS (Basic) | -2.19 | -2.64 | -2.23 | -1.74 | -0.70 | 4.90 | -0.80 | -0.41 | -0.51 | -0.54 | -0.54 | -0.41 | -0.48 | -0.49 | -0.57 | -0.49 | -0.32 | -0.52 | -0.38 | -0.49 | ||||||||||
| EPS (Diluted) | -3.08 | -2.64 | -5.09 | -1.74 | -0.70 | 4.88 | -0.80 | -0.41 | -0.51 | -0.54 | -0.54 | -0.41 | -0.48 | -0.49 | -0.57 | -0.49 | -0.32 | -0.52 | -0.38 | -0.49 | ||||||||||
| Shares Outstanding | 6.22M | 5.42M | 6.57M | 6.57M | 6.57M | 6.57M | 18.51M | 40.96M | 41.03M | 35.55M | 42.05M | 48.08M | 48.27M | 47.07M | 50.05M | 52.11M | 62.09M | 56.66M | 62.80M | 66.17M | ||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 4.43M | 5.42M | 2.88M | 6.57M | 6.57M | 6.60M | 18.51M | 40.96M | 41.03M | 35.55M | 42.05M | 48.08M | 48.27M | 47.07M | 50.05M | 52.11M | 62.09M | 56.66M | 62.80M | 66.17M | ||||||||||
| EBITDA | -13.63M | -14.31M | 30.32M | -8.96M | -10.87M | -10.11M | -16.35M | -20.06M | -24.17M | -22.65M | -25.91M | -24.52M | -26.99M | -26.83M | -31.62M | -28.50M | -25.03M | -34.20M | -27.81M | -37.20M |
Pull Enliven Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ELVN&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ELVN", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ELVN&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();